Inactive Instrument

Pharmacyclics, Inc. Stock

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

15-05-06	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
15-04-29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

15-05-06	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
15-04-29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
15-04-21	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
15-04-21	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
15-04-08	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
15-03-05	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
15-03-05	Wall Street closes up slightly ahead of jobs report	RE
15-03-05	AbbVie : CEO says new form of Humira could thwart generics	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-03-05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
14-06-02	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

16-01-07	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
16-01-07	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
16-01-07	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
16-01-07	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
16-01-07	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

15-03-05	Wall Street se reprend un peu dans un climat d'attente
15-03-05	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
15-03-05	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
15-03-05	Début d'année en fanfare pour les fusions dans la pharmacie
15-03-05	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	2013-01-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-0.36%	+6.27%	+3.94%	+10.48%	50.25B
REVOLUTION MEDICINES, INC.	-1.02%	+0.00%	+410.72%	+609.67%	40.39B
IQVIA HOLDINGS INC.	-0.08%	+6.32%	+26.46%	-5.24%	34.38B
BEONE MEDICINES AG	-1.05%	+7.37%	+26.96%	+61.42%	34.4B
CELLTRION, INC.	-4.19%	-1.84%	+3.76%	+32.17%	26.32B
ASCENDIS PHARMA A/S	+0.31%	+0.65%	-	-	16.64B
MEDPACE HOLDINGS, INC.	-3.20%	+2.51%	+70.24%	+130.50%	16.14B
EUROFINS SCIENTIFIC SE	+0.93%	+1.14%	+15.03%	+22.21%	13.71B
IONIS PHARMACEUTICALS, INC.	+0.43%	+5.69%	+100.57%	+100.57%	13.75B
Average	-0.91%	+3.57%	+82.21%	+120.22%	27.33B
Weighted average by Cap.	-0.96%	+4.03%	+93.51%	+138.33%

Employees

Sector